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S odium-glucose cotransporter 2 (SGLT2) inhibitors suppress glucose reabsorption in the renal proximal 
tubule and improve glycemic control.  Recent studies 
have reported the evidence that SGLT2 inhibitors reduce 
the risk of cardiovascular and renal events [1-4].  Based 
on the results of these large-scale clinical trials showing 
organ-protective effects,  the algorithm described by the 
American Diabetes Association (ADA) in its Standards 
of Medical Care in Diabetes-2020 recommends SGLT2 
inhibitors as a second-line therapy option following 
metformin,  especially in patients with atherosclerotic 
cardiovascular disease (ASCVD),  heart failure (HF) or 
chronic kidney disease (CKD) [5].  Furthermore,  the 2019 
European Society of Cardiology/European Association 
for the Study of Diabetes (ESC/EASD) Guidelines on 
diabetes regard SGLT2 inhibitors as a first-line therapy 
for diabetic patients with heart disease [6].  This is a 
significant turning point in the US and Europe,  where 
biguanides have long been the first-line strategy for dia-
betes.
SGLT2 inhibitors are also recognized for their weight 
loss effect and favorable effects on the lipid metabolism.  
Therefore,  they are expected to constitute a “compre-
hensive” therapeutic strategy for type 2 diabetes with 
metabolic syndrome.  With regard to the lipid metabo-
lism in particular,  it has been reported that SGLT2 
inhibitors improve the overall lipid profile by decreasing 
triglycerides (TGs) and increasing high-density lipo-
protein cholesterol (HDL-C) [7].
Here,  we report the case of a type 2 diabetic patient 
with significant worsening of the lipid profile including 
marked TG elevation during the administration of SGLT2 
inhibitors.  Although SGLT2 inhibitors are now widely 
used and play a central role in the treatment of diabetes,  
their proper use requires attention.
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A 43-year-old male with type 2 diabetes,  under treatment with 5 mg/day of dapagliflozin,  was referred to our 
hospital with upper left abdominal pain and marked hypertriglyceridemia (triglycerides [TGs],  5,960 mg/dl).  
He was also on a low-carbohydrate diet that promoted ketosis under sodium glucose cotransporter 2 (SGLT2) 
inhibitor administration.  Polyacrylamide gel electrophoresis revealed a remarkable increase in very-low-den-
sity lipoprotein,  a TG-rich lipoprotein particle synthesized in the liver using free fatty acids derived from adi-
pose tissue.  Although SGLT2 inhibitors generally improve the lipid profile,  under certain conditions such as a 
low-carbohydrate diet,  they may adversely exacerbate the lipid profile via ketosis.
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Case Presentation
A 43-year-old male with type 2 diabetes presented 
with upper left abdominal pain lasting for two weeks and 
marked TG elevation (5,960 mg/dl).  His primary care 
doctor suspected acute pancreatitis and referred him to 
our hospital.  The patient had been diagnosed with type 
2 diabetes at the age of 41 ((hemoglobin A1c [HbA1c],  
12.1%; fasting blood glucose [FBG],  243 mg/dl) and 
administration of the dipeptidyl peptidase-4 (DPP-4) 
inhibitor teneligliptin was started.  Two months before 
the patient’s first visit to our hospital,  his therapy for 
diabetes was switched from 20 mg/day of teneligliptin to 
5 mg/day of dapagliflozin,  an SGLT2 inhibitor,  because of 
poor glycemic control (HbA1c,  11.6%; BG,  291 mg/dl).  
He was also on a low-carbohydrate diet,  restricted to 
90-120 grams per day with the aim of losing weight over 
a period of one month.  According to an interview with 
a registered dietitian,  his lipid intake was normal and he 
was on a protein-based diet.
In addition,  the patient had dyslipidemia and was 
being treated with 2 mg/day of pitavastatin calcium.  
Under pitavastatin administration,  his levels of TG,  
low-density lipoprotein cholesterol (LDL-C) and HDL-C 
were 500-800 mg/dl,  100-140 mg/dl and 40-45 mg/dl,  
respectively.  He had no family history of dyslipidemia,  
stroke or coronary artery disease,  but his mother has 
type 2 diabetes.  The patient neither drinks nor smokes,  
and does not frequently drink sugar-sweetened bever-
ages.
At his first visit to our hospital,  the patient’s body 
mass index was 30.1 kg/m2 (height,  160 cm; body weight,  
77.0 kg) and his weight was approximately 5 kg less than 
it had been 3 months earlier.  Time-course changes in his 
examination findings are shown in Table 1.  His blood test 
results at his first visit (Day 1) revealed marked TG,  total 
cholesterol (TC) and free fatty acid (FFA) elevation (fast-
ing TG,  4,632 mg/dl; TC,  594 mg/dl; FFA,  5.66 mEq/l) 
and decreased HDL-C (17 mg/dl).  Urinary ketone mea-
sured by dipstick was strongly positive,  but no metabolic 
acidosis was detected by arterial blood gas analysis (pH,  
7.415; pO2,  94.0 mmHg; pCO2,  35.0 mmHg; HCO3-,  
22.0 mmol/l; base excess,  -1.3 mmol/l).  Regarding 
exocrine pancreatic enzymes,  the patient’s elastase-1 level 
had increased to 1,160 ng/dl,  though his amylase,  lipase,  
SPan-1 and DU-PAN-2 levels were within normal range.  
With respect to liver function,  his transaminase levels 
were elevated.  Abdominal plain computed tomography 
(CT) showed only marked fatty liver,  but no evidence of 
the suspected acute pancreatitis such as swelling in the 
pancreas or increased adipose tissue density around the 
pancreas.
Considering the possibility that a low-carbohydrate 
diet combined with the SGLT2 inhibitor might cause 
ketosis,  the administration of dapagliflozin was discon-
tinued and the patient was instructed to eat at least 150 g 
of rice per meal as a staple food.  Teneligliptin was resumed 
at a dosage of 20 mg/day and insulin therapy with insu-
lin degludec was initiated at a dosage of 4 units per day.
At his return visit 3 days after the initial visit (Day 4),  
the patient’s gastrointestinal symptoms had disappeared 
and his TG level had decreased to 2,968 mg/dl.  His uri-
nary ketone excretion had also decreased,  although it 
had not disappeared completely.  His venous ketone 
body levels were mildly elevated (total ketone bodies,  
175 μmol/l; acetoacetate,  77.0 μmol/l; 3-hydroxybu-
tyrate,  97.5 μmol/l).  After confirming that his endoge-
nous insulin-secreting capacity was maintained (serum 
C-peptide reactivity [CPR],  4.11 ng/ml),  we discontin-
ued insulin degludec and asked the patient’s primary 
care doctor to administer 500 mg/day of metformin.  On 
Day 39,  the patient’s TG level decreased to 452 mg/dl 
and urinary ketone bodies were negative (Table 1).
Lipoproteins were analyzed by polyacrylamide gel 
electrophoresis (PAGE).  On Day 1,  PAGE revealed a 
remarkable increase in very low-density lipoprotein 
(VLDL) and the almost complete disappearance of LDL 
fraction (Fig.1A).  On Day 39,  on the other hand,  PAGE 
detected a significant rise in HDL and LDL,  and a rela-
tive decrease in VLDL (Fig. 1B).
After these results,  the patient’s treatment for dys-
lipidemia was changed from 2 mg/day of pitavastatin 
calcium to 0.2 mg/day of pemafibrate,  and his post-
prandial TG levels were found to be 190-350 mg/dl.
Discussion
SGLT2 inhibitors selectively inhibit SGLT2 in the renal 
proximal tubules and suppress glucose reabsorption,  
resulting in the promotion of urine glucose excretion.  
In addition to the positive effects on diabetes through 
urine glucose excretion,  SGLT2 inhibitors have been 
reported to improve insulin resistance,  hypertension 
and obesity [8].  They have also been reported to have 
favorable effects on the lipid profile,  such as increased 
HDL-C and decreased TG associated with hepatic glu-
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coneogenesis enhancement,  although the detailed 
mechanisms remain unknown [7].
In the present case,  the administration of SGLT2 
inhibitors was initially expected to improve the patient’s 
obesity and lipid profile,  but conversely,  it eventually 
caused marked hypertriglyceridemia.  Dyslipidemia in 
diabetes is often associated with elevated LDL-C and TG 
and decreased HDL-C,  based on insulin resistance.  
Impaired insulin action,  which is often observed in type 
2 diabetes,  causes the activation of hormone-sensitive 
lipase (HSL) in adipocytes and the degradation of adipose 
tissue triglycerides,  resulting in elevated FFA release into 
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Table 1　 Time-course changes in examination findings and medication
Day 1 Day 4 Day 39
HbA1c (%) 13.0 - 10.0
BG (mg/dl) 184 (fasting) 333 (PPG 2H) 154 (fasting)
IRI (μU/ml) 8.6 - 14.5
TC (mg/dl) 594 478 222
HDL-C (mg/dl) 17 23 46
TG (mg/dl) 4632 2968 452
LDL-C (mg/dl)
(direct measurement) 62 88 130
non HDL-C (mg/dl) 577 455 176
FFA (mEq/l) 5.66 - 1.01
AST (U/l) 82 - 34
ALT (U/l) 52 - 52
γ-GTP (U/l) 156 - 84
T-Bil (mg/dl) 0.6 - -
ChE (U/l) 438 - -
Alb (g/dl) 4.4 - -
PLT (×103/μl) 341 - -
FIB-4 Index 1.43 - -
U-Ketone （3＋） （1＋） （－）
Body weight (kg) 77.0 78.0 81.4
Medication
dapaglifrozin 5 mg ×
teneligliptin 20 mg
insulin degludec 4u ×
metformin 500 mg











Fig. 1　  Polyacrylamide gel electrophoresis (PAGE) of serum lipoproteins.   
A: Day 1.   
B: Day 39.
the blood.  The blood-borne FFAs flow into the liver,  
where they play roles in increased VLDL production and 
secretion as a substrate for TG synthesis.  In addition,  
the decreased activity of insulin also impairs lipoprotein 
lipase (LPL) activity and VLDL-TG catabolism,  result-
ing in hypertriglyceridemia.
The following mechanism was considered to be the 
cause of the marked hypertriglyceridemia following 
SGLT2 inhibitor administration in the present case.  A 
strict low-carbohydrate diet in combination with the 
SGLT2 inhibitor impaired hepatic glycolysis and pro-
moted lipolysis in adipose tissue and the release of FFAs 
into the blood [9].  An oversupply of FFAs to the liver 
enhanced β-oxidation in the mitochondria,  resulting in 
increased VLDL synthesis and secretion [10].  On the 
other hand,  since LPL activity was decreased due to 
insulin resistance,  it appeared that the catabolism of 
VLDL and intermediate-density lipoprotein (IDL) did 
not proceed,  resulting in elevated TG-rich lipoproteins 
and marked hypertriglyceridemia (Fig. 2) [11-16].  The 
upper left abdominal pain that led the patient to be 
referred to our hospital with suspected pancreatitis was 
considered to be associated with ketosis mediated by 
increased β-oxidation.  In addition,  at his first visit to 
our hospital,  a weight loss of 5 kg over 3 months was 
observed and eventually ascribed to ketosis.  However,  
it may have been difficult for the patient to recognize 
this weight loss,  as it had been masked by the SGLT2 
inhibitors and the low-carbohydrate diet.
In this case,  only elastase-1,  an exocrine pancreatic 
enzyme,  was elevated.  Elastase-1 has a long half-life,  
and once it increases,  it takes 2-4 weeks to normalize.  
Therefore,  high elastase-1 levels may persist even after 
other pancreatic enzymes are reduced and normalized.  
Although the possibility of acute pancreatitis occurring 
a few weeks before the patient’s first visit to our hospital 
cannot be completely ruled out,  we diagnosed his 
abdominal symptoms as being due to ketosis,  compre-
hensively considering the levels of other pancreatic 
enzymes,  CT findings,  medical history and the pres-
ence of ketosis.  During the patient’s clinical course,  his 
abdominal symptoms rapidly disappeared as the ketosis 
improved.
SGLT2 inhibitors are currently a central therapeutic 
strategy for diabetes worldwide due to their beneficial 
effects on HF,  CKD,  body weight and lipid profiles,  as 
well as on glycemic control.  On the other hand,  there 
are some points to be noted regarding the safety of SGLT2 
inhibitors,  such as the potential for genital and urinary 
tract infections,  hypoglycemia when combined with 
sulfonylureas or insulin,  and an increased risk of keto-
acidosis.  Ketoacidosis under SGLT2 inhibitor adminis-
tration in particular is often accompanied by only mod-
erately increased blood glucose levels and is known as 
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Fig. 2　 Assumed mechanism: regulation of glucose and lipid metabolism during dietary carbohydrate restriction with SGLT2 inhibitors.  
TG,  triglyceride; VLDL,  very low-density lipoprotein; IDL,  intermediate-density lipoprotein; LDL,  low-density lipoprotein; LPL,  lipoprotein 
lipase; HTGL,  hepatic triglyceride lipase.
euglycemic diabetic ketoacidosis (DKA) [17].  The U.S.  
Food and Drug Administration (FDA) warns about and 
identifies potential DKA-triggering factors such as acute 
illness,  reduced caloric or fluid intake,  reduced insulin 
dose and a history of alcohol intake (http://www.fda.
gov/downloads/Drugs/DrugSafety/UCM446954.pdf).
The present study has the limitation that the chylo-
microns identified by agarose gel electrophoresis,  LPL 
activity and ApoE phenotype have not yet been evalu-
ated.
In recent years,  dietary habits have diversified,  and 
patients with a strict carbohydrate-restricted diet or an 
imbalanced diet may have an increased risk of DKA when 
such a diet is combined with SGLT2 inhibitors.  In con-
clusion,  although SGLT2 inhibitors generally improve 
the lipid profile,  under certain conditions such as a 
low-carbohydrate diet,  they may adversely exacerbate 
the lipid profile via ketosis.
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